Therapeutic approaches using IL4I1-derived AKAs may serve as potential treatments for regulating myeloid cell-driven inflammation, and improving CNS remyelination in inflammatory demyelinating diseases such as MS. The gene discussed is IL4I1; the disease is myeloid sarcoma.